Annual Report

Overview

The report states that the company recorded approximately RMB1,230,867,000 in 2025 revenue, while continuing product development and obtaining six national patent certificates. It also reports 1,081 employees at year-end, including 466 female employees. The Group's business review describes ongoing expansion of pharmaceutical products, R&D activities, and production capacity.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: Ends 31 December 2025
Publication date: 27 March 2026
Language: English, Chinese
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services